Wordt geladen...
Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
Ticagrelor is the first reversible, direct-acting, potent P2Y(12) receptor antagonist in management of acute coronary syndromes. It is rapidly absorbed and extensively metabolized. AR-C124910XX, the major active metabolite, antagonizes the P2Y(12) receptor at approximately equal potency. The metabol...
Bewaard in:
| Gepubliceerd in: | Front Pharmacol |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5374142/ https://ncbi.nlm.nih.gov/pubmed/28408884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00176 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|